Amr Menshawy

Amr Menshawy

Auto-generated profile, based on publicly available information

Amr Menshawy

Faculty of Medicine, Al-Azhar University, Al-Azhar Medical Students' Association, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Melanoma Research
Verified
Journal Article
Closed access
AMAmr Menshawy
Amr Menshawy
AEAbdelrahman A. Eltonob
Abdelrahman A. Eltonob
SBSarah A. Barkat
Sarah A. Barkat
AGAhmed Ghanem
Ahmed Ghanem
MMMahmoud M. Mniesy
Mahmoud M. Mniesy
AEAhmed Elgebaly
Ahmed Elgebaly
Nivolumab, a completely human programmed death-1 inhibitor antibody, was first approved by the Food and Drug Administration for patients with advanced malignant melanoma resistant to other modalities of treatment. In 2015, it received approval as the first line of treatment for malignant melanoma. We aimed to synthesize evidence from published randomized-controlled trials on the safety and efficacy of nivolumab, either alone or in combination with ipilimumab, in the management of advanced unresectable melanoma. We searched the following electronic databases: PubMed, Scopus, Web of Science, and Cochrane Central. The records retrieved were screened for eligibility. Time-to-event data were pooled as Hazard ratio using the generic inverse variance method and dichotomous data were pooled as relative risk (RR) in a random-effects model. We used Review Manager 5.3 software for windows. Four unique randomized-controlled trials (five reports) with a total of 1910 patients (nivolumab group, n=1207 and control group, n=703) were included. The overall effect estimate favored nivolumab plus ipilimumab versus ipilimumab alone in terms of the objective response rate [RR: 3.58, 95% confidence interval (CI): 2.08–6.14], the complete response rate (RR: 5.93, 95% CI: 2.45–14.37), the partial response rate (RR: 2.80, 95% CI: 2.16–3.64), the stable disease rate (RR: 0.56, 95% CI: 0.41–0.76), and progression-free survival (hazard ratio: 0.67, 95% CI: 0.60–0.74). The pooled studies were homogenous. Similar results were obtained for nivolumab monotherapy versus chemotherapy comparison. Nivolumab alone or combined with ipilimumab significantly improved the overall and complete response rates compared with ipilimumab alone. In addition, nivolumab resulted in longer progression-free survival with a comparable safety profile.

1 November 2019 in Journal of Gynecology Obstetrics and Human Reproduction
Verified
Journal Article
Closed access
AMAmr Menshawy
Amr Menshawy
AIAmmar Ismail
Ammar Ismail
MAMohamed Abdel-Maboud
Mohamed Abdel-Maboud
AEAlaa Alaa El-Din
Alaa Alaa El-Din
AEAhmed Elgebaly
Ahmed Elgebaly
AAAhmed Abbas
Ahmed Abbas

19 October 2019 in Current Enzyme Inhibition
Verified
Journal Article
Open access
PDF file
EBEshak I. Bahbah
Eshak I. Bahbah
AAAhmed Ramadan Abdalla
Ahmed Ramadan Abdalla
KAKhalid Abdelshafy
Khalid Abdelshafy
AAAhmed Diaa Almohandes
Ahmed Diaa Almohandes
AMAmr Menshawy
Amr Menshawy
Ahmed NegidaAhmed Negida
Ahmed Negida
Objective: The aim of this study is to synthesize the evidence about the efficacy of Olanzapine for the prevention of CINV. Methods: A computer literature search of PubMed, EBSCO, Ovid, and Cochrane CENTRAL databases has been conducted. Studies were screened for eligibility and data were extracted. The proportion of patients with complete response (CR) and those with no nausea were pooled as risk ratio (RR) in a fixed effect model meta-analysis using Review Manager Version 5.3 for windows. Results: Nine randomized controlled trials (n=1572) were pooled in the final analysis. In all studies, olanzapine was given as 10 mg PO. Olanzapine was superior to active control in terms of CR rate in acute phase (RR 1.12, 95% CI [1.02, 1.22], p=0.01]), delayed phase (RR 1.31, 95% CI [[1.10, 1.56], p=0.002), and overall phase (RR 1.30, 95% CI [1.09, 1.55], p=0.004). Rates of no nausea were significantly higher in olanzapine 10 mg group compared to active control group in acute phase (RR 1.20, 95% CI [1.04, 1.38], p=0.01), delayed phase (RR 1.72, 95% CI [1.42, 2.08], p Conclusion: Olanzapine is a well-tolerated drug for cancer patients and has shown superiority against conventional antiemetics for the prevention of CINV.